703 POSTER A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor

Plummer, R ; Vidal, L ; Perrett, R ; Spicer, J ; Stopfer, P ; Shahidi, M ; Temple, G ; Futreal, A ; Calvert, H ; de Bono, J

European journal of cancer supplements, , Vol.5 (4), p.108-108 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível